INTRODUCTION: The purpose of the study was to evaluate the cost differences between robot-assisted radical prostatectomy (RARP) and open radical prostatectomy (ORP) in various census regions of the United States because RARP has been reported to be more expensive than ORP with significant regional cost variations in radical prostatectomy (RP) cost across the United States. PATIENTS AND METHODS: International Classification of Diseases, Ninth Revision, Clinical Modification codes were used to identify patients with prostate cancer who underwent RARP or ORP from the Nationwide Inpatient Sample (NIS) database from 2009 to 2011. Hospital costs were compared using the Wilcoxon rank sum test and multivariable linear regression analysis adjusting for age, sex, race, comorbidities, and hospital characteristics. RESULTS: From the NIS database, 24,636 RARP and 13,590 ORP procedures were identified and evaluated. The lowest cost overall was in the South; the highest cost RARP was in the West and for ORP in the Northeast. In multivariable analysis, adjusted according to patient and hospital characteristics, RARP was 43.3% more costly in the Midwest, 37.2% more costly in the South, and 39.1% more costly in the West (P < .0001 for all). In contrast, the cost for RARP in the Northeast was 12.8% less than for ORP (P < .0001). CONCLUSION: Cost for RP significantly varies within the nation and in most regions it is significantly greater for RARP than for ORP. ORP in the Northeast is more costly than RARP. Further research is needed to delineate the reason for these differences and to optimize the cost of RP. Published by Elsevier Inc.
INTRODUCTION: The purpose of the study was to evaluate the cost differences between robot-assisted radical prostatectomy (RARP) and open radical prostatectomy (ORP) in various census regions of the United States because RARP has been reported to be more expensive than ORP with significant regional cost variations in radical prostatectomy (RP) cost across the United States. PATIENTS AND METHODS: International Classification of Diseases, Ninth Revision, Clinical Modification codes were used to identify patients with prostate cancer who underwent RARP or ORP from the Nationwide Inpatient Sample (NIS) database from 2009 to 2011. Hospital costs were compared using the Wilcoxon rank sum test and multivariable linear regression analysis adjusting for age, sex, race, comorbidities, and hospital characteristics. RESULTS: From the NIS database, 24,636 RARP and 13,590 ORP procedures were identified and evaluated. The lowest cost overall was in the South; the highest cost RARP was in the West and for ORP in the Northeast. In multivariable analysis, adjusted according to patient and hospital characteristics, RARP was 43.3% more costly in the Midwest, 37.2% more costly in the South, and 39.1% more costly in the West (P < .0001 for all). In contrast, the cost for RARP in the Northeast was 12.8% less than for ORP (P < .0001). CONCLUSION: Cost for RP significantly varies within the nation and in most regions it is significantly greater for RARP than for ORP. ORP in the Northeast is more costly than RARP. Further research is needed to delineate the reason for these differences and to optimize the cost of RP. Published by Elsevier Inc.
Authors: Danielle A Southern; Barbara Roberts; Alun Edwards; Stafford Dean; Peter Norton; Lawrence W Svenson; Erik Larsen; Peter Sargious; David C W Lau; William A Ghali Journal: Can J Public Health Date: 2010 Jan-Feb
Authors: Vincenzo Ficarra; Giacomo Novara; Walter Artibani; Andrea Cestari; Antonio Galfano; Markus Graefen; Giorgio Guazzoni; Bertrand Guillonneau; Mani Menon; Francesco Montorsi; Vipul Patel; Jens Rassweiler; Hendrik Van Poppel Journal: Eur Urol Date: 2009-01-25 Impact factor: 20.096
Authors: Paul L Nguyen; Xiangmei Gu; Stuart R Lipsitz; Toni K Choueiri; Wesley W Choi; Yin Lei; Karen E Hoffman; Jim C Hu Journal: J Clin Oncol Date: 2011-03-14 Impact factor: 44.544
Authors: Colin B Begg; Elyn R Riedel; Peter B Bach; Michael W Kattan; Deborah Schrag; Joan L Warren; Peter T Scardino Journal: N Engl J Med Date: 2002-04-11 Impact factor: 91.245
Authors: William T Lowrance; James A Eastham; Caroline Savage; A C Maschino; Vincent P Laudone; Christopher B Dechet; Robert A Stephenson; Peter T Scardino; Jaspreet S Sandhu Journal: J Urol Date: 2012-04-11 Impact factor: 7.450
Authors: Christian Bolenz; Stephen J Freedland; Brent K Hollenbeck; Yair Lotan; William T Lowrance; Joel B Nelson; Jim C Hu Journal: Eur Urol Date: 2012-09-05 Impact factor: 20.096
Authors: Prasanna Sooriakumaran; Abhishek Srivastava; Shahrokh F Shariat; Phillip D Stricker; Thomas Ahlering; Christopher G Eden; Peter N Wiklund; Rafael Sanchez-Salas; Alexandre Mottrie; David Lee; David E Neal; Reza Ghavamian; Peter Nyirady; Andreas Nilsson; Stefan Carlsson; Evanguelos Xylinas; Wolfgang Loidl; Christian Seitz; Paul Schramek; Claus Roehrborn; Xavier Cathelineau; Douglas Skarecky; Greg Shaw; Anne Warren; Warick J Delprado; Anne-Marie Haynes; Ewout Steyerberg; Monique J Roobol; Ashutosh K Tewari Journal: Eur Urol Date: 2013-11-24 Impact factor: 20.096
Authors: Felix Preisser; Sebastiano Nazzani; Elio Mazzone; Sophie Knipper; Marco Bandini; Zhe Tian; Alexander Haese; Fred Saad; Kevin C Zorn; Francesco Montorsi; Shahrokh F Shariat; Markus Graefen; Derya Tilki; Pierre I Karakiewicz Journal: World J Urol Date: 2018-10-12 Impact factor: 4.226
Authors: Florian Rudolf Schroeck; Bruce L Jacobs; Sam B Bhayani; Paul L Nguyen; David Penson; Jim Hu Journal: Eur Urol Date: 2017-03-31 Impact factor: 20.096
Authors: Margit Pohle; Ahmed Magheli; Tom Fischer; Carsten Kempkensteffen; Jonas Busch; Hannes Cash; Kurt Miller; Stefan Hinz Journal: Adv Ther Date: 2017-01-04 Impact factor: 3.845
Authors: Brian M Shinder; Nicholas J Farber; Robert E Weiss; Thomas L Jang; Isaac Y Kim; Eric A Singer; Sammy E Elsamra Journal: Robot Surg Date: 2017-08-17